Daktari Diagnostics is developing the CarePlatform™, an immunoassay-based, highly portable point-of-care device that integrates proprietary detection technology, automated whole-blood sample preparation in a single-use disposable cartridge, and wireless cloud connectivity. The platform is designed to deliver HIV viral load counts from whole blood in under 30 minutes and aims to address diagnostic access gaps in global health settings. Daktari’s viral load test quantifies virion-associated p24 protein rather than free p24, and a preliminary study showed strong correlation with standard RT-PCR viral load values. The company reports the potential to achieve a limit of detection equivalent to 1,000 copies/mL, a clinically relevant threshold defined by WHO. Daktari is collaborating with Partners for Health and Development in Africa (PHDA) and Dr. Julius Oyugi (University of Nairobi) on the project. The work is intended to help reach patients in developing countries who are presently inaccessible to lab-based systems. Daktari Diagnostics develops portable diagnostic instruments that can be deployed in pharmacies, physicians’ offices and remote health facilities worldwide. The company’s first application on its platform, Daktari CD4, completed clinical validation studies in January 2015 and is slated for global commercialization in 2015. Daktari plans to expand its platform with Daktari Virology, which will add molecular tests for HCV and HIV in a non‑PCR format. The company is led by founder and CEO Bill Rodriguez, M.D. Daktari is based in Cambridge, USA. Financially, the company closed a $15.5M Series D in early 2015. Daktari Diagnostics develops simple, accurate, and affordable handheld HIV monitoring devices. The company focuses on delivering critical diagnostic test results to clinicians and patients across the globe. Its team of engineers, scientists, physicians, and global health experts is dedicated to creating high-performance products. Products are specifically designed for resource-poor markets. Daktari raised $7 million in a venture capital round, according to an SEC filing. Twenty-six separate investors participated in the financing. Daktari Diagnostics develops point-of-care diagnostic systems aimed at global health, focusing on simple, accurate, and affordable tests. Its system is designed to analyze small volumes of blood or other fluids for use in any type of health care setting. The company intends to use the financing to complete development and bring to market initial products for monitoring HIV patients worldwide and to expand its point-of-care product development pipeline. The underlying technology was initially developed at Massachusetts General Hospital. Daktari was founded in 2008 and is led by CEO Bill Rodriguez, M.D. The company is based in Cambridge, Mass., is currently hiring, and recently raised $10M in the reported financing. Daktari Diagnostics develops a hand-held point-of-care device that counts CD4 cells to determine immune function in HIV/AIDS patients. The device is designed to provide on-site CD4 counts, avoiding the time-consuming and costly lab-based testing common in many parts of Africa and other developing countries. The company is Cambridge, Mass.-based. Financially, Daktari disclosed an equity financing of $1.8 million in an SEC filing and has previously completed a $2.8 million round in Sept. 2009 and later added $820,000 in June. The SEC filing states the new capital came from 32 unnamed investors and names several directors and the CEO on prior securities documents. Daktari's product aims to enable faster point-of-care assessment of HIV progression by providing CD4 counts without centralized labs.

Total raised

$36M

Funding rounds

5

Latest round

Grant

Latest activity

Dec 2016